OMER - オメロス (Omeros Corporation)

OMERのニュース

   Omeros's Narsoplimab Shows Encouraging Action In Critically Ill COVID-19 Patients  2021/05/28 16:00:45 Business Insider Markets
Omeros Corporation (NASDAQ: OMER ) has announced preliminary results from the second cohort (n=10) of critically ill…
   Omeros Reports Preliminary Results From Critically Ill COVID-19 Patients Treated With Narsoplimab  2021/05/28 13:22:35 Business Insider Markets
(RTTNews) - Omeros Corp. (OMER) announced preliminary results from the second cohort of critically ill COVID-19 patients treated with narsoplimab in Bergamo, Italy. 80% of the patients were recovered, survived and discharged. Meanwhile 2 deaths were occurred. This is because of 76-year-old man had complications of pre-existing cardiomyopathy.
   Omeros posts preliminary results from COVID-19 patients treated with narsoplimab  2021/05/28 12:59:06 Seeking Alpha
   Bitcoin's use in crime is a bizarre regulatory fixation because any monetary system can be used unlawfully, a crypto fund co-founder says  2021/05/28 10:14:09 Business Insider
Summary List Placement Policymakers' concern over bitcoin's use in illicit payments is strange, since any form of monetary exchange can be used illegally, Nic Carter, a partner at crypto fund Castle Island Ventures, told Bloomberg this week. "The concern about illicit activities is an odd one," he said. "Any monetary system is always going to be used for crime, as well as more salubrious purposes." The recent bitcoin downturn was partly fueled by fears over its use in ransom payments to the hackers who shut down the Colonial Pipeline in the US this month, along with global changes in regulation. "All of the data that we have seen, and this is kind of eminently traceable, because bitcoin is this relatively transparent system, indicates that in absolute and relative terms, the dollar is used for illicit purposes, far more than bitcoin," Carter said. "So the crime angle is a pretty curious one. I mean, we didn't ban dollars because Pablo Escobar had heaps of dollars in his basement." Bitcoin was last trading 9% lower at $35,620 on Friday.
   Bitcoin's use in crime is a bizarre regulatory fixation because any monetary system can be used unlawfully, a crypto fund co-founder says  2021/05/28 10:14:09 Business Insider
Summary List Placement Policymakers' concern over bitcoin's use in illicit payments is strange, since any form of monetary exchange can be used illegally, Nic Carter, a partner at crypto fund Castle Island Ventures, told Bloomberg this week. "The concern about illicit activities is an odd one," he said. "Any monetary system is always going to be used for crime, as well as more salubrious purposes." The recent bitcoin downturn was partly fueled by fears over its use in ransom payments to the hackers who shut down the Colonial Pipeline in the US this month, along with global changes in regulation. "All of the data that we have seen, and this is kind of eminently traceable, because bitcoin is this relatively transparent system, indicates that in absolute and relative terms, the dollar is used for illicit purposes, far more than bitcoin," Carter said. "So the crime angle is a pretty curious one. I mean, we didn't ban dollars because Pablo Escobar had heaps of dollars in his basement." Bitcoin was last trading 9% lower at $35,620 on Friday.
   Wedbush Stick to Their Hold Rating for Omeros Corp By Investing.com  2021/01/20 12:13:57 Investing.com
Wedbush Stick to Their Hold Rating for Omeros Corp
   Biologics License Application for Narsoplimab in HSCT-TMA Accepted for Priority Review by U.S. FDA  2021/01/19 13:30:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced today that the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) has been accepted for filing by the U.S. Food and Drug Administration (FDA). The BLA has been granted Priority Review with an FDA action date of July 17, 2021 under the Prescription Drug User Fee Act (PDUFA). FDA also indicated in its filing letter that the
   Omeros to Present at the 39th Annual J.P. Morgan Healthcare Conference  2021/01/11 21:30:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 39th Annual J.P. Morgan Healthcare Conference this week. This conference is being held as a virtual conference this year. The presentation is scheduled for Wednesday, January 13, 2021 at 10:50 a.m. EST. The presentation will be webcast. The live and archived webcasts can be accessed on the investor relations section of the company
   CMS Confirms Continued Separate Payment for Omeros’ FDA-Approved OMIDRIA® in Ambulatory Surgery Centers  2020/12/03 12:30:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced today that the Centers for Medicare & Medicaid Services (CMS) confirmed separate payment in ambulatory surgery centers (ASCs) for Omeros’ cataract surgery drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3%. In its final rule directed to the Medicare outpatient prospective payment system (OPPS) and the ASC payment system for calendar year 2021, CMS confirmed that OMIDRIA qualifies for separate payment
   Omeros Submits its Biologics License Application to U.S. FDA for Narsoplimab in HSCT-TMA  2020/11/18 14:00:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced that it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Narsoplimab targets mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of complement, and has received breakthrough ther
   Global Opioid Use Disorder Market (Covid 19 Update) Future Growth Analysis, Business Demand and Opportunities to 2027 || Teva Pharmaceutical Industries Ltd.; Omeros Corporation; Camurus; Hikma Pharmaceuticals PLC; Titan Pharmaceuticals, Inc  2020/10/22 10:13:20 OpenPR
Data Bridge Market Research has recently added a concise research on the Global Opioid Use Disorder Market- Industry Trends and Forecast to 2026. A reliable Global Opioid Use Disorder Market report contains market data that can be relatively essential when
   Omeros (NASDAQ:OMER) Earns Buy Rating from Analysts at Bank of America  2020/10/20 12:45:05 Zolmax News
Analysts at Bank of America started coverage on shares of Omeros (NASDAQ:OMER) in a report issued on Tuesday, The Fly reports. The firm set a “buy” rating on the biopharmaceutical company’s stock. Several other analysts also recently commented on the stock. HC Wainwright reduced their target price on shares of Omeros from $34.00 to $32.00 […]
   Omeros’ OMS906 Data Presented at Complement-based Drug Development Summit  2020/10/16 12:30:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4th Complement-based Drug Development Summit. OMS906 is the company’s lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of the complement system’s alternative pathway. The presentation about the inhibition of the alternative pathway by targeting MASP-3 was made by Jason Cummings, Ph.D., Omeros’ Associate Directo
   Omeros Schedules Webcast to Present Final Efficacy Results from Narsoplimab BLA for the Treatment of HSCT-TMA  2020/10/15 12:00:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the final results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will be presented in a webcast on Thursday, October 22, 2020 at 8:30 a.m. ET by Miguel Perales, M.D, Chief of the Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center, and Alessandro Rambaldi, MD, Professor, Department of Oncology and
   Omeros Provides Update on Separate Payment for OMIDRIA® in the ASCs  2020/10/01 13:00:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today provided an update on the status of reimbursement for its cataract surgery drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3%. The two-year extension of pass-through status provided by Congress through the Consolidated Appropriations Act of 2018 for OMIDRIA expired today. Omeros is actively engaged in requesting from the Centers for Medicare and Medicaid Services (CMS) and the Department of Health and Human

calendar